Top

Published in:

01-04-2013 | Short Communication

Increased HMGB1 serum levels and altered HMGB1 expression in patients with psoriasis vulgaris

Authors: Tao Chen, Zai-pei Guo, Li Li, Ling Wang, Rui-zhen Jia, Na Cao, Sha Qin, Meng-meng Li

Published in: Archives of Dermatological Research | Issue 3/2013

Abstract

High mobility group box-1 (HMGB1) has been implicated as a pro-inflammatory cytokine in the pathogenesis of various inflammatory and autoimmune diseases. However, information about HMGB1 in inflammatory skin diseases is unknown. Herein, we investigated the serum HMGB1 levels and tissue HMGB1 expression in patients with psoriasis vulgaris (PV) and atopic dermatitis (AD). Serum levels of HMGB1 in patients with PV and AD were detected by enzyme-linked immunosorbent assay (ELISA). The expression of HMGB1 in lesional skin was evaluated by immunohistochemistry and immunofluorescence. Protein levels of HMGB1 in the nuclear fraction and cytoplasmic fraction were determined by western blot. Serum levels of HMGB1 in patients with PV but not AD were significantly higher than those in nornal controls. Moreover, serum HMGB1 levels were correlated with the severity of PV according to PASI socres. Furthermore, by immunohistochemistry and immunofluorescence, we showed that the expression of HMGB1 in normal skin was almost completely restricted to the nucleus. However, abundant cytoplasmic expression of HMGB1 was observed in the epidermis in lesional skin of PV patients. In addition, western blot data indicated that HMGB1 expression was in the nucleus protein and was absent in the cytoplasm protein in control group. In contrast, HMGB1 expression in the cytoplasmic fraction was detectable in AD patients and more distinct in PV patients. Taken together, this study provides first observations on the association of HMGB1 with PV, and showed the elevated HMGB1 serum levels and altered HMGB1 distribution in lesional skin in patients with PV. We suggest that HMGB1 might be involved in the pathogenesis of PV.

Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M (2010) HMGB1 in systemic lupus Erythematosus: its role in cutaneous lesions development. Autoimmun Rev 9:661–665CrossRefPubMed

Anderson KS, Petersson S, Wong J, Shubbar E, Lokko NN, Carlström M et al (2010) Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol 163:1085–1089CrossRefPubMed

Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH et al (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101:2652–2660CrossRefPubMed

Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG (2009) Human Langerhans cells induce distinct IL-22-producing CD4 + T cells lacking IL-17 production. Proc Natl Acad Sci USA 106:21795–21800CrossRefPubMed

Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB et al (2007) Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 13:210–215CrossRefPubMed

He Z, Jin L, Liu ZF, Hu L, Dang EL, Feng ZZ et al (2012) Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis. Br J Dermatol 167:191–193CrossRefPubMed

Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342CrossRefPubMed

Oktayoglu P, Em S, Tahtasiz M, Bozkurt M, Ucar D, Yazmalar L et al (2012) Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life. Rheumatol Int. doi:10.1007/s00296-012-2578-y PubMed

Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M et al (2005) Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 52:3639–3645CrossRefPubMed

10.

Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H et al (2003) IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170:3890–3897PubMed

11.

Rossini A, Zacheo A, Mocini D, Totta P, Facchiano A, Castoldi R et al (2008) HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. J Mol Cell Cardiol 44:683–693CrossRefPubMed

12.

Sawa H, Ueda T, Takeyama Y, Yasuda T, Shinzeki M, Nakajima T et al (2006) Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol 12:7666–7670PubMed

13.

Schierbeck H, Lundbäck P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U et al (2011) Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 17:1039–1044CrossRefPubMed

14.

Shi Y, Sandoghchian Shotorbani S, Su Z, Liu Y, Tong J, Zheng D et al (2012) Enhanced HMGB1 expression may contribute to Th17 cells activation in rheumatoid arthritis. Clin Dev Immunol 2012:295081CrossRefPubMed

15.

Straino S, Di Carlo A, Mangoni A, De Mori R, Guerra L, Maurelli R et al (2008) High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 128:1545–1553CrossRefPubMed

16.

Su Z, Sun C, Zhou C, Liu Y, Zhu H, Sandoghchian S et al (2011) HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17-cell expansion. Eur J Immunol 41:3586–3595CrossRefPubMed

17.

Zimmermann M, Koreck A, Meyer N, Basinski T, Meiler F, Simone B et al (2011) TNF-like weak inducer of apoptosis (TWEAK) and TNF-α cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol 127:200–207CrossRefPubMed

Title: Increased HMGB1 serum levels and altered HMGB1 expression in patients with psoriasis vulgaris
Authors: Tao Chen
Zai-pei Guo
Li Li
Ling Wang
Rui-zhen Jia
Na Cao
Sha Qin
Meng-meng Li
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Archives of Dermatological Research / Issue 3/2013
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-013-1330-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased HMGB1 serum levels and altered HMGB1 expression in patients with psoriasis vulgaris

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities

Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients

Validation of Dermaphot® for the assessment of steroid-induced skin atrophy

Possible contribution of GSTP1 and other xenobiotic metabolizing genes to vitiligo susceptibility

Selected variants of the melanocortin 4 receptor gene (MC4R) do not confer susceptibility to female pattern hair loss

Interleukin-1 family members are enhanced in psoriasis and suppressed by vitamin D and retinoic acid